Bioedexa Pharmaceuticals shares are trading lower. The company released patient updates on progression-free survival and overall survival from the ongoing MAGIC-1 study of MTX110 in recurrent Glioblastoma.
Portfolio Pulse from Benzinga Newsdesk
Bioedexa Pharmaceuticals shares are trading lower following the release of patient updates from the MAGIC-1 study of MTX110 in recurrent Glioblastoma, which reported on progression-free survival and overall survival.
October 17, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bioedexa Pharmaceuticals shares are declining after the company released updates on the MAGIC-1 study of MTX110, focusing on progression-free survival and overall survival in recurrent Glioblastoma.
The release of patient updates from the MAGIC-1 study likely disappointed investors, leading to a decline in Bioedexa's stock price. The focus on progression-free survival and overall survival suggests that the results may not have met investor expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100